IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11236140 B1

PDFFull Text
Date of Patent:
Feb. 01, 2022

Filed:

Feb. 21, 2020

Interleukin 15 fusion protein for tumor targeting therapy

Applicant:

BJ Bioscience Inc., Hangzhou, CN;

Inventors:

Zhong Wang, Guangzhou, CN;

Qing Li, Guangzhou, CN;

Assignee:

BJ Bioscience Inc., Hangzhou, CN;

Attorney:

Sheppard Mullin Richter & Hampton LLP

Primary Examiner:

Zachary C Howard

Int. Cl.
CPC ...
C07K 14/54 (2006.01); C07K 14/71 (2006.01); C07K 19/00 (2006.01); A61K 38/20 (2006.01); A61K 38/17 (2006.01); A61K 47/68 (2017.01); A61P 35/04 (2006.01); C07K 14/715 (2006.01); A61K 38/08 (2019.01); C07K 7/06 (2006.01); A61P 35/00 (2006.01); C12N 15/62 (2006.01); C12N 15/64 (2006.01); C12N 15/63 (2006.01); C12N 15/11 (2006.01);
U.S. Cl.
CPC ...
C07K 14/5443 (2013.01); A61K 38/08 (2013.01); A61K 38/1793 (2013.01); A61K 38/20 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07K 7/06 (2013.01); C07K 14/7155 (2013.01); C07K 19/00 (2013.01); C07K 2319/30 (2013.01); C07K 2319/70 (2013.01); C12N 15/11 (2013.01); C12N 15/62 (2013.01); C12N 15/63 (2013.01); C12N 15/64 (2013.01);
Abstract

Disclosed is a tumor-targeting fusion protein comprising at least (i) a IL-15 peptide or a variant or functional fragment thereof, (ii) a IL-15Rα polypeptide or a variant or functional fragment thereof, (iii) a Fc domain or a variant or functional fragment thereof, and (iv) a RGD polypeptide or a variant thereof. The fusion protein is preferably configured as RGD polypeptide-Fc domain-IL-15 polypeptide-IL-15Rα polypeptide. The tumor-targeting fusion proteins provided herein improves the anti-tumor effects of IL-15 and prolongs the half-life of IL-15, while targeting tumor sites and acting upon tumor cells. In addition, the fusion proteins are capable of being expressed at high efficiency and purified. The high efficiency of anti-tumor activity enables the fusion proteins to be an excellent candidate for tumor immunotherapy.

Find Patent Forward Citations

Loading…